

Margarita Kirienko

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4274035/publications.pdf>

Version: 2024-02-01

50
papers

2,134
citations

201385

27
h-index

233125

45
g-index

55
all docs

55
docs citations

55
times ranked

2972
citing authors

#	ARTICLE	IF	CITATIONS
1	PET/CT radiomics in breast cancer: Mind the step. <i>Methods</i> , 2021, 188, 122-132.	1.9	44
2	Climbing the steps of the evidence-based medicine pyramid: highlights from <i>Annals of Nuclear Medicine</i> 2019. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1293-1301.	3.3	13
3	Increased incidence of interstitial pneumonia detected on [18F]-FDG-PET/CT in asymptomatic cancer patients during COVID-19 pandemic in Lombardy: a casualty or COVID-19 infection?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 777-785.	3.3	16
4	Deep learning in Nuclear Medicine—focus on CNN-based approaches for PET/CT and PET/MR: where do we stand?. <i>Clinical and Translational Imaging</i> , 2021, 9, 37-55.	1.1	14
5	Prevalence of interstitial pneumonia suggestive of COVID-19 at 18F-FDG PET/CT in oncological asymptomatic patients in a high prevalence country during pandemic period: a national multi-centric retrospective study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2871-2882.	3.3	11
6	Distributed learning: a reliable privacy-preserving strategy to change multicenter collaborations using AI. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3791-3804.	3.3	21
7	Radiomics and gene expression profile to characterise the disease and predict outcome in patients with lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3643-3655.	3.3	53
8	State-of-the-art of FAPI-PET imaging: a systematic review and meta-analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4396-4414.	3.3	85
9	The five “W”s and “How” of Targeted Alpha Therapy: Why? Who? What? Where? When? and How?. <i>Rendiconti Lincei</i> , 2020, 31, 231-247.	1.0	12
10	Imaging-Based Prediction of Molecular Therapy Targets in NSCLC by Radiogenomics and AI Approaches: A Systematic Review. <i>Diagnostics</i> , 2020, 10, 359.	1.3	51
11	Interdisciplinarity: an essential requirement for translation of radiomics research into clinical practice—a systematic review focused on thoracic oncology. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2020, 39, 146-156.	0.1	5
12	CT, [18F]FDG-PET/CT and clinical findings before and during early Covid-19 onset in a patient affected by vascular tumour. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1769-1770.	3.3	12
13	FDG-PET/CT findings highly suspicious for COVID-19 in an Italian case series of asymptomatic patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1649-1656.	3.3	63
14	Computed tomography (CT)-derived radiomic features differentiate prevascular mediastinum masses as thymic neoplasms versus lymphomas. <i>Radiologia Medica</i> , 2020, 125, 951-960.	4.7	52
15	Interdisciplinaridad: un requerimiento esencial para la traslación de investigación en radiómica a la práctica clínica. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2020, 39, 146-156.	0.0	14
16	Methodological framework for radiomics applications in Hodgkin’s lymphoma. <i>European Journal of Hybrid Imaging</i> , 2020, 4, 9.	0.6	13
17	Quantitative imaging biomarkers in nuclear medicine: from SUV to image mining studies. Highlights from <i>annals of nuclear medicine</i> 2018. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2737-2745.	3.3	18
18	PSMA expression level predicts differentiated thyroid cancer aggressiveness and patient outcome. <i>EJNMMI Research</i> , 2019, 9, 93.	1.1	31

#	ARTICLE	IF	CITATIONS
19	Reply to: "Lack of evidence and criteria to evaluate artificial intelligence and radiomics tools to be implemented in clinical settings"; European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2814-2815.	3.3	0
20	Computed tomography based radiomic signature as predictive of survival and local control after stereotactic body radiation therapy in pancreatic carcinoma. PLoS ONE, 2019, 14, e0210758.	1.1	58
21	Towards clinical application of image mining: a systematic review on artificial intelligence and radiomics. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2656-2672.	3.3	177
22	PET/CT radiomics in breast cancer: promising tool for prediction of pathological response to neoadjuvant chemotherapy. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1468-1477.	3.3	107
23	The "3M" Approach to Cardiovascular Infections: Multimodality, Multitracers, and Multidisciplinary. Seminars in Nuclear Medicine, 2018, 48, 199-224.	2.5	38
24	PET/MRI in Infection and Inflammation. Seminars in Nuclear Medicine, 2018, 48, 225-241.	2.5	38
25	Ability of FDG PET and CT radiomics features to differentiate between primary and metastatic lung lesions. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1649-1660.	3.3	112
26	Prediction of disease-free survival by the PET/CT radiomic signature in non-small cell lung cancer patients undergoing surgery. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 207-217.	3.3	143
27	Texture analysis and machine learning to characterize suspected thyroid nodules and differentiated thyroid cancer: Where do we stand?. European Journal of Radiology, 2018, 99, 1-8.	1.2	85
28	Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 751-758.	3.3	10
29	Convolutional Neural Networks Promising in Lung Cancer T-Parameter Assessment on Baseline FDG-PET/CT. Contrast Media and Molecular Imaging, 2018, 2018, 1-6.	0.4	57
30	Hodgkin lymphoma and imaging in the era of anti-PD-1/PD-L1 therapy. Clinical and Translational Imaging, 2018, 6, 417-427.	1.1	8
31	EP-1362: Random forest analysis to predict Disease-Free Survival using FDG-PET and CT in Lung Cancer. Radiotherapy and Oncology, 2018, 127, S743-S744.	0.3	1
32	Allogeneic Stem Cell Transplantation (Allo-SCT) after Treatment with Programmed Cell Death-1 (PD-1) Checkpoint Inhibitors for Relapsed/Refractory Classic Hodgkin Lymphoma (R/R cHL) Is Associated with an Unprecedented Low Relapse Rate. Blood, 2018, 132, 2185-2185.	0.6	0
33	Toxicity and efficacy of salvage carbon 11 choline positron emission tomography/computed tomography-guided radiation therapy in patients with lymph node recurrence of prostate cancer. BJU International, 2017, 119, 406-413.	1.3	43
34	PET Radiomics in NSCLC: state of the art and a proposal for harmonization of methodology. Scientific Reports, 2017, 7, 358.	1.6	127
35	[18F]FDG PET/CT features for the molecular characterization of primary breast tumors. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1945-1954.	3.3	61
36	The Role of Nuclear Cardiac Imaging in Infective Endocarditis. Current Cardiovascular Imaging Reports, 2017, 10, 1.	0.4	3

#	ARTICLE	IF	CITATIONS
37	[18F]FDG-PET/CT texture analysis in thyroid incidentalomas: preliminary results. <i>European Journal of Hybrid Imaging</i> , 2017, 1, 3.	0.6	24
38	FDG PET CT as theranostic imaging in diagnosis of non-small cell lung cancer. <i>Frontiers in Bioscience - Landmark</i> , 2017, 22, 1713-1723.	3.0	16
39	Radiomics based analysis to predict local control and survival in hepatocellular carcinoma patients treated with volumetric modulated arc therapy. <i>BMC Cancer</i> , 2017, 17, 829.	1.1	77
40	FDG-PET/CT Predicts Outcome in Oropharyngeal Carcinoma Patients Undergoing Intensity Modulated Radiation Therapy with Dose Escalation to FDG-avid Tumour Volumes. <i>Current Radiopharmaceuticals</i> , 2017, 10, 102-110.	0.3	3
41	Predictive value of 18F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 404-413.	3.3	47
42	The role of PET/CT in the evaluation of patients affected by limbic encephalitis: A systematic review of the literature. <i>Journal of Neuroimmunology</i> , 2015, 284, 44-48.	1.1	29
43	Radiation Treatment of Lymph Node Recurrence from Prostate Cancer: Is ¹¹ C-Choline PET/CT Predictive of Survival Outcomes?. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1836-1842.	2.8	35
44	Imaging biomarkers in prostate cancer: role of PET/CT and MRI. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 644-655.	3.3	57
45	[11C]Choline PET/CT predicts survival in hormone-naive prostate cancer patients with biochemical failure after radical prostatectomy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 877-884.	3.3	38
46	Writing PET into existence. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 7-10.	3.3	2
47	Predictive value of pre-therapy 18F-FDG PET/CT for the outcome of 18F-FDG PET-guided radiotherapy in patients with head and neck cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 21-31.	3.3	60
48	11C-Choline PET/CT as a guide to radiation treatment planning of lymph-node relapses in prostate cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1270-9.	3.3	72
49	Prostate cancer as a paradigm of multidisciplinary approach? Highlights from the Italian young radiation oncologist meeting. <i>Tumori</i> , 2013, 99, 637-649.	0.6	18
50	Clinical use of PET-CT data for radiotherapy planning: What are we looking for?. <i>Radiotherapy and Oncology</i> , 2010, 96, 277-279.	0.3	50